Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Dose-finding and Pharmacokinetic Study of RTA 402 (CDDOMe) Administered Orally for 21 Days of a 28-day Cycle in Patients With Advanced Solid Tumors or Lymphoid Malignancies

NCT00529438 is registered in ClinicalTrials.gov with Biogen as lead sponsor.

NCT NCT00529438
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00529438 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Dose-finding and Pharmacokinetic Study of RTA 402 (CDDOMe) Administered Orally for 21 Days of a 28-day Cycle in Patients With Advanced Solid Tumors or Lymphoid Malignancies
Lead sponsor
Biogen
Phase
Phase 1
Overall status
Completed
Start date
April 30, 2006
Completion date
December 1, 2008
Enrollment
47 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors, lymphoid malignancies